Late break abstract submission
Late break abstract submission has now closed.
Abstract submission deadline: Monday 14 August 2023
Notification of acceptance/regrets: Monday 4 September 2023
Please read all information on this page before submitting your abstract.
- The first author listed for each abstract is considered to be the presenting author who will be the primary contact for all correspondence regarding the abstract.
- Presenting authors are responsible for proofreading before submission. No edits will be allowed in submitted abstracts for typing, spelling, or grammatical errors.
- Abstracts which are not correctly formatted will not be reviewed.
- Abstracts must be submitted in English.
Research abstracts are eligible, whether or not their content has been presented at meetings of other scientific societies, as long as they meet the following criteria:
- relevant to the field of pharmacoepidemiology as broadly defined
- results have not been published (except in abstract form) either on-line or in printed full form before January 1 of the year of the meeting, and
- results have not been presented at a previous ISPE meeting.
Presenting in-person at the conference venue, Sheraton Grand Bangalore Hotel at Brigade Gateway, Bangalore, India. In-person presenters will print an A0 (1189 mm high x 841 mm wide) size poster to display in the poster gallery and must be in attendance at their poster at a specific time to discuss with interested attendees.
Topics for abstract submission are:
A. Pharmaceutical policy and administration
B. Pharmacoepidemiology and Pharmacovigilance research methods
C. Drug safety risk monitoring, evaluation and prevention
D. Pharmacogenomics research and drug safety
E. Evidence-based medicine
F. Evidence-based pharmacy
G. Drug utilization evaluation studies
H. Rational drug use
I. Pharmacoepidemiology and traditional medicines
J. Prevention of medication errors and drug misuse/abuse
K. Rare disease and orphan medicines
L. Post-marketing drug effectiveness and safety evaluation
M. Prevention and treatment of drug-induced diseases
N. Other related fields
Abstract title: must not exceed 12 words.
Abstract text: must not exceed 300 words (excluding the Title, Authors, and Affiliations).
Do not reference institution names, locations, or funding sources in the abstract.
Abstracts should include the following headings:
Keywords: list not more than four keywords describing your research. Graphics and tables cannot be submitted as part of your abstract.
Author names and affiliations:
Up to 15 authors and affiliations may be included on each abstract. All authors must have consented to the abstract submission.
You will receive an email acknowledging receipt of your abstract submission. If you do not receive this email and, after checking your spam/junk folder, please contact Expert Events via firstname.lastname@example.org.
All submitted abstracts will be reviewed by at least 3 reviewers.
In evaluating each abstract, reviewers will be unaware of authors or institutions involved with the work described in the abstract. (Abstracts will be suitably anonymised by the program secretariat before being sent out to reviewers).
The Program Committee will assign accepted abstracts either to oral or poster presentation, and the reviewers’ decision is final.
The Organising Committee reserves the right to accept or decline any submissions and to select the presentation format.
Presenting authors will be notified of their acceptance status on Monday 4 September 2023 and must inform any co-author(s).
All presenting authors must have registered and paid to attend the conference by Friday 22 September 2023.
Accepted abstracts will be published in the conference program only if the presenting author has registered for the conference.
All enquiries regarding abstracts and the submission process should be directed to the ACPE15 Program Secretariat, Expert Events.
PO Box 351, Hamilton Central QLD 4007 Australia
Tel: +61 7 3848 2100 | Email: email@example.com